Advertisement

Contact
searchSearch
HMP Global

ADVERTISEMENT

Interviews

Dr Craig Chepke
Exclusive Interview
Dr Craig Chepke Appointed Scientific Director of Psych Congress, to Co-Chair Upcoming Elevate Meeting
05/21/2024
Meagan Thistle
Dr Craig Chepke discusses his aspirations in his new role, shares insights from his career journey, and reflects on the impact of Psych Congress events on his clinical practice.
Dr Craig Chepke discusses his aspirations in his new role, shares insights from his career journey, and reflects on the impact of Psych Congress events on his clinical practice.
Dr Craig Chepke discusses his...
05/21/2024
Psych Congress Network
Nurses Hoberg and Kempf
Videos
Maintaining Composure When Treating and Caring for Patients With Dementia
03/21/2024

Featuring Amber Hoberg, PMHNP-BC, and Brooke Kempf, PMHNP-BC

Featuring Amber Hoberg, PMHNP-BC, and...
Nurses Hoberg and Kempf discuss how clinicians and caregivers alike can maintain composure and patience when treating patients with dementia.
Nurses Hoberg and Kempf discuss how clinicians and caregivers alike can maintain composure and patience when treating patients with dementia.
Nurses Hoberg and Kempf discuss...
03/21/2024
Psych Congress Network
Bradley Corr, MD
Conference Coverage
Rucaparib Maintenance Therapy Improved Progression-Free Survival Among Patients With Recurrent or Metastatic Endometrial Cancer
03/21/2024

Featuring Bradley Corr, MD

Featuring Bradley Corr, MD
At the 2024 SGO Annual Meeting on Women’s Cancers, Bradley Corr, MD, discusses the results from a study evaluating rucaparib maintenance therapy for patients with metastatic or recurrent endometrial cancer.
At the 2024 SGO Annual Meeting on Women’s Cancers, Bradley Corr, MD, discusses the results from a study evaluating rucaparib maintenance therapy for patients with metastatic or recurrent endometrial cancer.
At the 2024 SGO Annual Meeting...
03/21/2024
Oncology

Advertisement

Constantino Peña, MD, Miami Cancer Institute
Videos
The Importance of a Multidisciplinary Approach in Interventional Oncology
03/21/2024

Featuring Constantino Peña, MD

Featuring Constantino Peña, MD ...
Constantino Peña, MD, discusses the importance of a multidisciplinary approach within the field of interventional oncology.
Constantino Peña, MD, discusses the importance of a multidisciplinary approach within the field of interventional oncology.
Constantino Peña, MD, discusses...
03/21/2024
IO Learning
Jing-Zhou Hou, MD, PhD
Videos
Clinical and Demographic Factors Impacting Treatment Selection for Patients With CLL in Community Oncology Settings
03/21/2024

Featuring Jing-Zhou Hou, MD, PhD

Featuring Jing-Zhou Hou, MD, PhD ...
Jing-Zhou Hou, MD, PhD, discusses how the standard of care for CLL has evolved among community oncologists since 2020 and how clinical and demographic factors impact treatment selection.
Jing-Zhou Hou, MD, PhD, discusses how the standard of care for CLL has evolved among community oncologists since 2020 and how clinical and demographic factors impact treatment selection.
Jing-Zhou Hou, MD, PhD,...
03/21/2024
Journal of Clinical Pathways
Jack Jennings, MD, PhD, Washington University in St Louis
Videos
Treatment of Primary and Metastatic Sarcoma
02/06/2024

Featuring Jack Jennings, MD, PhD

Featuring Jack Jennings, MD, PhD ...
At the 2024 SIO Annual Meeting, Jack Jennings, MD, PhD, discussed the role of the interventional oncologist when treating primary or metastatic sarcomas of the bone or soft tissue.
At the 2024 SIO Annual Meeting, Jack Jennings, MD, PhD, discussed the role of the interventional oncologist when treating primary or metastatic sarcomas of the bone or soft tissue.
At the 2024 SIO Annual Meeting,...
02/06/2024
IO Learning

Advertisement

Saby George, MD
Conference Coverage
Subcutaneous Nivolumab Noninferior to Intravenous Administration Among Patients With Clear Cell Renal Cell Carcinoma
01/27/2024

Featuring Saby George, MD 

Featuring Saby George, MD 
Saby George shares insights from the CheckMate 67T evaluating the subcutaneous administration of nivolumab for patients with clear cell renal cell carcinoma, compared with the intravenous administration.
Saby George shares insights from the CheckMate 67T evaluating the subcutaneous administration of nivolumab for patients with clear cell renal cell carcinoma, compared with the intravenous administration.
Saby George shares insights from...
01/27/2024
Oncology
Michiel van der Heijden, MD 
Conference Coverage
Enfortumab Vedotin Plus Pembrolizumab Potential New Standard of Care for Advanced Urothelial Carcinoma in the First-Line Setting
01/26/2024

Featuring Michiel van der Heijden, MD 

Featuring Michiel van der Heijden, MD...
Michiel van der Heijden, MD, discusses the subgroup analyses of the phase 3 EV-302 study, evaluating enfortumab vedotin plus pembrolizumab among patients with locally advanced or metastatic urothelial carcinoma in the first-line setting.
Michiel van der Heijden, MD, discusses the subgroup analyses of the phase 3 EV-302 study, evaluating enfortumab vedotin plus pembrolizumab among patients with locally advanced or metastatic urothelial carcinoma in the first-line setting.
Michiel van der Heijden, MD,...
01/26/2024
Oncology
Thierry André, MD, Saint Antoine Hospital
Videos
Nivolumab Plus Ipilimumab Yields Superior PFS vs Chemotherapy for First-Line Treatment of Metastatic Colorectal Cancer
01/23/2024

Featuring Thierry André, MD

Featuring Thierry André, MD
Thierry Andre, MD, discusses the first results from the CheckMate 8HW study exploring nivolumab plus chemotherapy for the first-line treatment of microsatellite instability-high, mismatch repair-deficient metastatic colorectal cancer.
Thierry Andre, MD, discusses the first results from the CheckMate 8HW study exploring nivolumab plus chemotherapy for the first-line treatment of microsatellite instability-high, mismatch repair-deficient metastatic colorectal cancer.
Thierry Andre, MD, discusses the...
01/23/2024
Oncology

Advertisement

Riccardo Lencioni, MD, University of Pisa School of Medicine
Videos
Addition of Durvalumab, Bevacizumab to TACE for Hepatocellular Carcinoma Improves PFS
01/23/2024

Featuring Riccardo Lencioni, MD

Featuring Riccardo Lencioni, MD ...
Ricardo Lencioni, MD, shares results from the phase 3 EMERALD-1 study which found the addition of durvalumab and bevacizumab to TACE improved progression-free survival among patients with hepatocellular carcinoma, compared with TACE alone.
Ricardo Lencioni, MD, shares results from the phase 3 EMERALD-1 study which found the addition of durvalumab and bevacizumab to TACE improved progression-free survival among patients with hepatocellular carcinoma, compared with TACE alone.
Ricardo Lencioni, MD, shares...
01/23/2024
Oncology

Advertisement

Advertisement

Advertisement

Advertisement

Upcoming Events

September 18 ⁠–⁠ September 20
September 21 ⁠–⁠ September 22
AMP Europe
September 30 ⁠–⁠ October 2
October 1 ⁠–⁠ October 2
SAWC Fall
October 2 ⁠–⁠ October 5
October 5 ⁠–⁠ October 6
SMASH
October 14 ⁠–⁠ October 16
Lymphoma, Leukemia, and Myeloma
October 16 ⁠–⁠ October 19
October 19 ⁠–⁠ October 20
October 26 ⁠–⁠ October 27
See Full Calendar

Advertisement

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Privacy Policy Terms of Use